Panacea Venture is a life sciences venture capital firm with a global vision, focusing on investing in and incubating early-stage companies with disruptive technologies and discoveries that address unmet medical needs. Their strategy involves a "borderless execution model" and an "asset-centric" approach, investing across all life science subsectors with a therapeutic focus, and employing a "barbell strategy" that includes early-stage, expansion, and public company investments.
100% of their portfolio is in Biotech & Life Sciences. They made 2 investments in the last 12 months. Average disclosed round size is $43.8M (across 3 rounds with reported amounts).
Portfolio
4
Fund Size
$276M
Top Stage
Series A
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| SSeismic Pharma | Unknown | — | Mar 2026 |
 Kainova Therapeutics | Series B | $32M | Feb 2026 |
| AActym Therapeutics | Series A | $59.5M | Oct 2023 |
 XWPharma | Series C | $40M | Sep 2020 |
Top Co-Investors
Illumina Ventures1 shared
Schroders Capital1 shared
Investissement Quebec1 shared
3B Future Health Fund1 shared
Viva BioInnovator1 shared
adMare BioInnovations1 shared
WI Harper1 shared
KTB Network1 shared
Trinity Ventures1 shared
Last updated: 21 April 2026